Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
…, K Tsukasaki, SP Yeh, A Shustov, A Hüttmann… - The Lancet, 2019 - thelancet.com
Background Based on the encouraging activity and manageable safety profile observed in
a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of …
a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of …
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
…, H Diedrich, HA Horst, A Hüttmann… - Blood, The Journal …, 2012 - ashpublications.org
Despite improvements in first-line therapies, published results on the treatment of relapsed
adult acute lymphoblastic leukemia (ALL) show that prognosis is still poor. The aim of the …
adult acute lymphoblastic leukemia (ALL) show that prognosis is still poor. The aim of the …
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a …
C Röllig, H Serve, A Hüttmann, R Noppeney… - The lancet …, 2015 - thelancet.com
Background Preclinical data and results from non-randomised trials suggest that the
multikinase inhibitor sorafenib might be an effective drug for the treatment of acute myeloid …
multikinase inhibitor sorafenib might be an effective drug for the treatment of acute myeloid …
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
…, MS Esfahani, CL Liu, U Dührsen, A Hüttmann… - Nature …, 2021 - nature.com
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the …
…, J Markova, J Meissner, M Feuring-Buske, A Hüttmann… - The Lancet, 2017 - thelancet.com
Background The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses…
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses…
[HTML][HTML] Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma
…, AM Newman, U Dührsen, A Hüttmann… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Outcomes for patients with diffuse large B-cell lymphoma remain heterogeneous,
with existing methods failing to consistently predict treatment failure. We examined the …
with existing methods failing to consistently predict treatment failure. We examined the …
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
…, H Serve, U Dührsen, A Hüttmann… - Blood, The Journal …, 2014 - ashpublications.org
This largest prospective multicenter trial for adult patients with Burkitt lymphoma/leukemia
aimed to prove the efficacy and feasibility of short-intensive chemotherapy combined with the …
aimed to prove the efficacy and feasibility of short-intensive chemotherapy combined with the …
[PDF][PDF] Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of resistance, …
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of resistance, …
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
…, T Pabst, M Vogelhuber, A Hüttmann… - The Lancet …, 2021 - thelancet.com
Background Combined-modality treatment consisting of chemotherapy and consolidation
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. …
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. …
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation
…, G Hartung, HA Horst, A Hüttmann… - Blood, The Journal …, 2011 - ashpublications.org
Nelarabine, a purine analog with T-cell specific action, has been approved for relapsed/refractory
T-cell acute lymphoblastic leukemia/lymphoma (ALL/LBL). This is a report of a single-…
T-cell acute lymphoblastic leukemia/lymphoma (ALL/LBL). This is a report of a single-…